Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9 Suppl 1 (Suppl 1), S3-8

Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer

Affiliations

Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer

Mark A Perlmutter et al. Rev Urol.

Abstract

This article reviews the issues and controversies relevant to the treatment of advanced prostate cancer with androgen deprivation therapy. Initially, diethylstilbestrol was used for achieving androgen deprivation, but was replaced by luteinizing hormone-releasing hormone (LHRH). Adverse events associated with LHRH agonists include the flare phenomenon, hot flashes, loss of libido, erectile dysfunction, depression, muscle wasting, anemia, and osteoporosis. Intermittent therapy has been advocated to reduce morbidity of treatment. The addition of an antiandrogen provides maximum androgen blockade. There remains controversy regarding the timing of the addition of an antiandrogen. Secondary hormonal therapies include antiandrogens, adrenal androgen inhibitors, and estrogens.

Similar articles

See all similar articles

Cited by 68 PubMed Central articles

See all "Cited by" articles

LinkOut - more resources

Feedback